Clinical trials: Acne Rosacea
Erythematotelangiectatic Rosacea, Papulopustular Rosacea
Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients
The objective of this study is to determine the efficacy and safety of PAC-14028 1% cream of Amorepacific Corporation in patients with erythema-telangiectatic or papulopustular rosacea
- Trial name
- NCT02052999
- Testing
- PAC-14028 cream 1%, Vehicle, Rozex gel 0.75%
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Amorepacific Corporation
Rosacea
Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea
To compare safety and efficacy of Perrigo's rosacea drug product compared to an FDA approved rosacea drug product in the treatment of facial erythema of rosacea.
- Trial name
- NCT02385240
- Testing
- Brimonidine Topical Gel, 0.33 percent (Perrigo), Brimonidine Topical Gel, 0.33 percent (Reference)
- Volunteers
- 552 people
- Sponsor
- Padagis LLC
Rosacea
CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea
This is a multicenter, randomized, double-blind, vehicle-controlled, parallel design study evaluating the efficacy and safety of CGB-400 Topical Gel for the treatment of inflammatory lesions of rosacea.
- Trial name
- NCT04886739
- Testing
- CGB-400, Vehicle Gel
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- CAGE Bio Inc.
Rosacea
Mirvaso® Utilisation and Patient Satisfaction Evaluation (MUSE)
The aim of the study is to evaluate the level of satisfaction among patients to whom Mirvaso® / Onreltea TM (trade mark) is prescribed.
- Trial name
- MUSE (NCT02637232)
- Testing
- Mirvaso® / Onreltea TM
- Where
- Canada
- Volunteers
- 301 people
- Sponsor
- Galderma R&D
Papulopustular Rosacea
A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
To assess the safety of S5G4T-1 when applied once daily for up to 40 weeks in participants with papulopustular rosacea who completed either Study SGT-54-01 (NCT03448939) or Study SGT-54-02 (NCT03564119).
- Trial name
- NCT03564145
- Testing
- S5G4T-1
- Where
- United States
- Volunteers
- 547 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Rosacea
To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea
To demonstrate the superiority of the efficacy of the test and reference products over that of the placebo control in the treatment of moderate facial rosacea.
- Trial name
- NCT03689010
- Testing
- Azelaic acid foam 15%, Finacea® (Azelaic acid Foam) 15%, Vehicle of the test product
- Where
- United States
- Volunteers
- 1,116 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Erythematotelangiectatic Rosacea
Feasibility Study: Ulthera System for the Treatment of Rosacea
Up to 12 subjects will be enrolled. Enrolled subjects will receive one or two Ultherapy treatments on the cheeks, depending on their assigned study group. Follow-up visits will occur 14, 30 and 90 days post-treatment.
- Trial name
- NCT01756027
- Testing
- Ulthera System providing one treatment per cheek, Ulthera System providing two treatments per cheek
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Ulthera, Inc
Rosacea
A Study to Determine the Safety and Efficacy of Atralin (Tretinoin 0.05%) Gel for the Treatment of Rosacea
To compare the efficacy and safety of tretinoin gel 0.05% to its vehicle when dosed once or twice daily in female subjects with rosacea.
- Trial name
- NCT00621218
- Testing
- tretinoin gel 0.05%, vehicle
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Coria Laboratories, Ltd.
Acne Rosacea
DMT310-005 Topical in the Treatment of Acne Rosacea
The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne rosacea.
- Trial name
- NCT05108025
- Testing
- Topical Powder
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Dermata Therapeutics
Rosacea, Acne Vulgaris
The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage
This study is an evaluation of the role of topical dissolved oxygen to lessen visible signs of photodamage using a select regimen of topical dissolved oxygen containing cosmeceutical products.
- Conditions
- Rosacea, Acne Vulgaris, Atopic Dermatitis, Seborrheic Dermatitis
- Trial name
- NCT00991198
- Testing
- Topical oxygen
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Aria Aesthetics Inc.
Papulopustular Rosacea (PPR)
Phase 3 Papulopustular Rosacea Study
The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be…
- Trial name
- NCT01493687
- Testing
- CD5024, Azelaic acid 15% Gel
- Where
- 50 sites in United States, Canada
- Volunteers
- 683 people
- Sponsor
- Galderma R&D
Erythema, Rosacea
Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea
This study will evaluate the safety and efficacy of AGN-199201 once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with rosacea.
- Trial name
- NCT02131636
- Testing
- AGN-199201, Vehicle to AGN-199201
- Where
- United States
- Volunteers
- 440 people
- Sponsor
- Allergan
Papulopustular Rosacea
Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea
This is a 12-week, multicenter, double-blind, randomized, two-arm, vehicle controlled study. Subjects will be randomized 1:1 to BPX-04 minocycline topical gel 1% or vehicle.
- Trial name
- PRISM (NCT03667222)
- Testing
- minocycline topical gel, topical gel vehicle
- Where
- 12 sites in United States
- Volunteers
- 207 people
- Sponsor
- BioPharmX, Inc.
Moderate to Severe Papulopustular Rosacea
Open Label Phase 2 Feasibility Study of BPX-04 Topical Minocycline Gel in Rosacea
An open label feasibility study using BPX-04 topical minocycline gel in papulopustular rosacea.
- Trial name
- NCT03050086
- Testing
- BPX-04 1% minocycline topical gel, BPX-04 2% minocycline topical gel, BPX-04 vehicle topical gel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- BioPharmX, Inc.
Erythematous (Type One) Rosacea
Dose Response Study of Patients With Erythematous Rosacea
The purpose of this study is to evaluate the dose-response relationship (effect) of four concentrations of V-101 Cream in patients with erythematous(redness) rosacea.
- Trial name
- NCT01186068
- Testing
- V-101, vehicle
- Where
- 7 sites in United States
- Volunteers
- 175 people
- Sponsor
- Vicept Therapeutics, Inc.
Bioequivalence
A Study Comparing Oxymetazoline 1% Cream to RHOFADE
randomized, double-blind, placebo controlled
- Trial name
- NCT05148689
- Testing
- Oxymetazoline hydrochloride Cream, 1%, Rhofade™ (oxymetazoline) cream, 1%
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Rosacea
Oracea Soolantra Association in Participants With Severe Rosacea
The main objective of this study is to evaluate the efficacy of Ivermectin 1% topical cream associated with Doxycycline 40 mg Modified release (MR) capsules versus Ivermectin 1% topical cream associated with Placebo in the…
- Trial name
- ANSWER (NCT03075891)
- Testing
- Ivermectin 1% cream, Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules
- Where
- 21 sites in United States, Canada and 1 more
- Volunteers
- 273 people
- Sponsor
- Galderma R&D
Papulopustular Rosacea
A 21 Day Pharmacokinetics Study in Papulopustular Rosacea
The purpose of this study is to characterize the pharmacokinetics of once daily topical gel and confirm that steady state conditions are reached under maximal use conditions following 3 weeks of daily applications.
- Trial name
- NCT02028286
- Testing
- CLS001
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Maruho Co., Ltd.
Rosacea
Assessment of Rosacea Patients' Clinical Trial Experiences
Taking part in medical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.
- Trial name
- NCT05747391
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Blepharitis, Meibomianitis
Treatment of Patients With Blepharitis and Facial Rosacea
To determine the safety and efficacy of sub-antimicrobial dose COL-101 in the treatment of patients who have both blepharitis and facial rosacea
- Conditions
- Blepharitis, Meibomianitis, Dry Eye
- Trial name
- NCT00560703
- Testing
- COL-101 (doxycycline, USP) capsules
- Where
- 8 sites in United States
- Volunteers
- 70 people
- Sponsor
- Galderma R&D